ReviewJournal of immunotherapy and precision oncology2021

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.

Andrew T Kuykendall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.